Cargando…
Polypharmacy in Older Adults with Alzheimer’s Disease
The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608980/ https://www.ncbi.nlm.nih.gov/pubmed/36295605 http://dx.doi.org/10.3390/medicina58101445 |
_version_ | 1784818902482550784 |
---|---|
author | Esumi, Satoru Ushio, Soichiro Zamami, Yoshito |
author_facet | Esumi, Satoru Ushio, Soichiro Zamami, Yoshito |
author_sort | Esumi, Satoru |
collection | PubMed |
description | The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults with Alzheimer’s disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer’s disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer’s disease, with a focus on psychotropic drugs. |
format | Online Article Text |
id | pubmed-9608980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96089802022-10-28 Polypharmacy in Older Adults with Alzheimer’s Disease Esumi, Satoru Ushio, Soichiro Zamami, Yoshito Medicina (Kaunas) Review The number of patients with Alzheimer’s disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer’s disease. Thus, older adults with Alzheimer’s disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer’s disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer’s disease, with a focus on psychotropic drugs. MDPI 2022-10-13 /pmc/articles/PMC9608980/ /pubmed/36295605 http://dx.doi.org/10.3390/medicina58101445 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Esumi, Satoru Ushio, Soichiro Zamami, Yoshito Polypharmacy in Older Adults with Alzheimer’s Disease |
title | Polypharmacy in Older Adults with Alzheimer’s Disease |
title_full | Polypharmacy in Older Adults with Alzheimer’s Disease |
title_fullStr | Polypharmacy in Older Adults with Alzheimer’s Disease |
title_full_unstemmed | Polypharmacy in Older Adults with Alzheimer’s Disease |
title_short | Polypharmacy in Older Adults with Alzheimer’s Disease |
title_sort | polypharmacy in older adults with alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608980/ https://www.ncbi.nlm.nih.gov/pubmed/36295605 http://dx.doi.org/10.3390/medicina58101445 |
work_keys_str_mv | AT esumisatoru polypharmacyinolderadultswithalzheimersdisease AT ushiosoichiro polypharmacyinolderadultswithalzheimersdisease AT zamamiyoshito polypharmacyinolderadultswithalzheimersdisease |